Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.
about
Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.Changes in the plasma membrane in metabolic disease: impact of the membrane environment on G protein-coupled receptor structure and function.Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.Beneficial effects of β-sitosterol on type 1 cholecystokinin receptor dysfunction induced by elevated membrane cholesterol.Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype.
P2860
Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Elimination of a cholecystokin ...... ut intrinsic agonist activity.
@ast
Elimination of a cholecystokin ...... ut intrinsic agonist activity.
@en
type
label
Elimination of a cholecystokin ...... ut intrinsic agonist activity.
@ast
Elimination of a cholecystokin ...... ut intrinsic agonist activity.
@en
prefLabel
Elimination of a cholecystokin ...... ut intrinsic agonist activity.
@ast
Elimination of a cholecystokin ...... ut intrinsic agonist activity.
@en
P2093
P2860
P1476
Elimination of a cholecystokin ...... ut intrinsic agonist activity.
@en
P2093
Aditya J Desai
Brad R Henke
Laurence J Miller
P2860
P304
P356
10.1016/J.BMCL.2015.03.051
P407
P577
2015-03-24T00:00:00Z